Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Endogard is a brand name for a veterinary anthelmintic drug primarily used for the treatment and control of various intestinal worms in dogs and cats. One common formulation combines the active ingredients praziquantel and oxibendazole. Praziquantel works by inducing contractions and paralysis in tapeworms and flukes, leading to their dislodgement and destruction. Oxibendazole, a benzimidazole, is effective against roundworms, strongyles, threadworms, pinworms, and lungworms by interfering with their energy metabolism. This combination provides broad-spectrum protection against common parasites like roundworms, hookworms, whipworms, and tapeworms, including hydatids. Other formulations of Endogard may include additional active ingredients such as febantel, pyrantel, and ivermectin, offering broader coverage against different types of parasites and even heartworm prevention. The drug is typically administered orally as a palatable tablet.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Endogard.